Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.64 |
| ▸ | PIM1 | P11309 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.64 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM4B | O94953 | 1/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7200696 | 0.87 | PARP1 (0.57) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL29701199 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1ALDH1A1PDPK1 | |
| SCHEMBL216176 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1ALDH1A1PDPK1 | |
| SCHEMBL643424 | 0.78 | ALDH1A1 (1.00) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL29873118 | 0.78 | PARP1 (0.74) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL1690531 | 0.78 | PARP1 (1.00) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL24819 | 0.78 | PARP1 (0.74) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL391295 | 0.78 | PIM1 (0.74) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL29967106 | 0.78 | PARP1 (0.74) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 | |
| SCHEMBL29898482 | 0.78 | ALDH1A1 (1.00) | PARP1CHEK1PIM1ALDH1A1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118575818-A | Application of compound shown in formula (I) in preventing and treating agricultural plant pathogenic fungal diseases | 广西田园生化股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2020108579-A1 | AMINO-SUBSTITUTED PYRIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2020-06-04 | — | — | WO | disclosed |
| US-10196383-B2 | Substituted quinazoline compounds and preparation and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-11-24 | — | — | US | disclosed |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-20150366868-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9199973-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2015-12-01 | — | — | US | disclosed |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-8912205-B2 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-20020147205-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035132-A1 | HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196383-B2 | Substituted quinazoline compounds and preparation and uses thereof | HCRTR1, HCRTR2, NPY5R | PARP1 3285/4885CHEK1 3864/4885PIM1 4472/4885 |
| US-20020147205-A1 | Heterocyclic compounds | ERBB2, ERBB3, ERBB4 | PARP1 2109/4885CHEK1 562/4885PIM1 582/4885 |
| US-20160339027-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PARP1 3104/4885CHEK1 286/4885PIM1 342/4885 |
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | PARP1 1602/4885CHEK1 73/4885PIM1 401/4885 |
| US-20150366868-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | PARP1 842/4885CHEK1 169/4885PIM1 3599/4885 |
| US-20160051551-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PARP1 3104/4885CHEK1 286/4885PIM1 342/4885 |
| US-20150065527-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ABL1, ERBB2, SRC | PARP1 3104/4885CHEK1 286/4885PIM1 342/4885 |
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | HCRTR1, HCRTR2, NPY5R | PARP1 3285/4885CHEK1 3864/4885PIM1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.